Integer Holdings (ITGR)
(Delayed Data from NYSE)
$131.49 USD
-0.94 (-0.71%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $131.54 +0.05 (0.04%) 7:54 PM ET
4-Sell of 5 4
C Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$131.49 USD
-0.94 (-0.71%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $131.54 +0.05 (0.04%) 7:54 PM ET
4-Sell of 5 4
C Value B Growth C Momentum B VGM
Zacks News
New Strong Buy Stocks for February 26th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Integer Holdings' (ITGR) 2019 View Strong Despite Rivalry
by Zacks Equity Research
Integer Holdings (ITGR) holds a solid position in the MedTech space but is still exposed to competition.
Integer Holdings' (ITGR) Q4 Earnings Beat, '19 View Strong
by Zacks Equity Research
Integer Holdings (ITGR) gains from the core Medical Sales segment's impressive performance in fourth-quarter 2018.
Integer (ITGR) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 13.04% and 1.74%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Integer (ITGR) Q4 Earnings Expected to Decline
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Integer Holdings (ITGR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ITGR) Outperforming Other Medical Stocks This Year?
Here's Why Investors Should Hold Patterson Companies Stock
by Zacks Equity Research
Patterson Companies (PDCO) gains from solid foothold in theAnimals Health business. However, the company is facing headwinds in the Dental segment.
Here's Why Investors Should Hold McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) gains traction from a solid foothold in the pharmaceutical and medical supplies distribution market. However, the company is grappled with regulatory constraints in Canada.
Omnicell (OMCL) Rides on Innovation Despite Cost Concerns
by Zacks Equity Research
Omnicell (OMCL) steadily sees a solid uptake of Omnicell XT. It also strikes various deals for the XR2 and IVX Workflow products.
Here's Why Investors Should Hold DENTSPLY (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY (XRAY) gains from strength in CAD/CAM dental imaging platform. However, sluggishness in the European business is worrisome.
LMNX or PACB: Which is a Better MedTech Investment Pick?
by Zacks Equity Research
Luminex (LMNX) scores higher than Pacific Biosciences (PACB) considering growth projections and fundamentals.
LabCorp, GENFIT Tie-Up to Develop Test for NASH, Widen Suite
by Zacks Equity Research
LabCorp (LH) continues to strengthen foothold in the diagnostics space through organic and inorganic means.
Here's Why You Should Add CVS Health to Your Portfolio Now
by Zacks Equity Research
CVS Health (CVS) is optimistic about synergies from Aetna deal which will help create a robust platform to serve individuals better.
Solid Global Business Aids NuVasive Amid Pricing Pressure
by Zacks Equity Research
Per NuVasive (NUVA), the international region holds significant growth opportunity. However, pricing pressure is a major headwind.
Here's Why You Should Invest in PerkinElmer (PKI) Stock Now
by Zacks Equity Research
Focus on emerging markets, improving margins and encouraging guidance provide PerkinElmer (PKI) a competitive edge in the MedTech space.
Here's Why Investors Should Bet on DexCom (DXCM) Right Now
by Zacks Equity Research
A solid guidance for 2018 and lucrative deals make DexCom (DXCM) a promising investment pick.
Cardiovascular Systems Gets Approvals in Japan, Widens Suite
by Zacks Equity Research
Cardiovascular Systems (CSII) continues to expand product portfolio to enhance market reach and versatility.
Here's Why You Should Invest in Wright Medical (WMGI) Now
by Zacks Equity Research
A bullish outlook and a wide array of products make Wright Medical (WMGI) a promising investment pick.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) is developing and acquiring new business lines that will complement its existing home care and hospice business.
Walgreens Counts on International Progress, Strategic Deals
by Zacks Equity Research
We are upbeat about Walgreens' (WBA) recent pact with Alphabet???s life sciences and healthcare segment, Verily, to coordinate on multiple projects with respect to chronic ailments.
Cardiovascular Systems Treats First Patient With Teleport
by Zacks Equity Research
Cardiovascular Systems (CSII) expands product portfolio to enhance market reach and versatility.
Here's Why You Should Invest in Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Hill-Rom's (HRC) M&A pipeline continues to be strong.
Boston Scientific (BSX) to Buy Residual Shares of Millipede
by Zacks Equity Research
Boston Scientific's (BSX) buyout of the leftover stake in Millipede will integrate the latter's IRIS Transcatheter Annuloplasty Ring System in the Structural Heart portfolio of the former.
Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) is performing well on the back of its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application.
Ecolab Inks Deal With Clearway for Renewable Power Project
by Zacks Equity Research
Ecolab's (ECL) virtual power purchase agreement with Clearway is part of a broader trend among corporate buyers. This will cover the company???s annual domestic energy use completely.